Evicenter
Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
Manufacturer
Novartis Pharmaceuticals Corporation
Prescribing information
Kisqali (opens in a new tab)
Questions
57
Last updated

All questions

Indication: Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer

4 questions · 3 sources

Indication

What is Kisqali approved for in metastatic breast cancer?

Note: The Prescribing Information also lists an early breast cancer indication (adjuvant treatment with an aromatase inhibitor), which this page does not cover.

Can Kisqali be used in premenopausal and postmenopausal women?

Can Kisqali be used after progression on endocrine therapy?

Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)

Can Kisqali be used in patients with visceral metastases?

Applies to Patients with HR-positive, HER2-negative advanced or metastatic breast cancer in pooled analyses of MONALEESA-2, MONALEESA-3, and MONALEESA-7